In addition to the current study and the aforementioned atherosclerosis study using Mapkapk2-/- mice [14], other studies have shown that MK2 inhibition can protect against ischemia/reperfusion injury and cardiac hypertrophy [33, 34], including in a diabetic setting [10]. Here, MAPKAPK2 is linked to atherosclerosis.